Doxa AB (publ) (DOXA.ST)
SEK 0.35
(-0.29%)
SEK 0.35
(-0.29%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 291.9 Million SEK | 1745.15% |
| 2022 | -33 Million SEK | -143.31% |
| 2021 | 76.2 Million SEK | 656.53% |
| 2020 | -13.69 Million SEK | -21.46% |
| 2019 | -11.27 Million SEK | -240.6% |
| 2018 | 8.01 Million SEK | 175.93% |
| 2017 | -10.56 Million SEK | 1.7% |
| 2016 | -10.74 Million SEK | 32.57% |
| 2015 | -15.93 Million SEK | 13.83% |
| 2014 | -18.48 Million SEK | 5.14% |
| 2013 | -19.49 Million SEK | 47.86% |
| 2012 | -37.37 Million SEK | 40.56% |
| 2011 | -62.88 Million SEK | -282.17% |
| 2010 | -16.45 Million SEK | 51.02% |
| 2009 | -33.59 Million SEK | 33.19% |
| 2008 | -50.28 Million SEK | -29.13% |
| 2007 | -38.94 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 6 Million SEK | 101.87% |
| 2024 Q1 | -320.1 Million SEK | -48.13% |
| 2023 Q1 | -44.6 Million SEK | 61.39% |
| 2023 FY | 542.9 Million SEK | 1745.15% |
| 2023 Q2 | 213.7 Million SEK | 579.15% |
| 2023 Q4 | -216.1 Million SEK | -138.55% |
| 2023 Q3 | 560.6 Million SEK | 162.33% |
| 2022 Q1 | -7 Million SEK | -107.76% |
| 2022 FY | -33 Million SEK | -143.31% |
| 2022 Q4 | -115.5 Million SEK | -1308.54% |
| 2022 Q3 | -8.2 Million SEK | -109.03% |
| 2022 Q2 | 90.8 Million SEK | 1397.14% |
| 2021 FY | 76.2 Million SEK | 656.53% |
| 2021 Q2 | -4.4 Million SEK | -46.67% |
| 2021 Q3 | -6.5 Million SEK | -47.73% |
| 2021 Q4 | 90.2 Million SEK | 1487.69% |
| 2021 Q1 | -3 Million SEK | -11.44% |
| 2020 Q1 | -2.8 Million SEK | -925.64% |
| 2020 Q3 | -4.1 Million SEK | 0.0% |
| 2020 Q2 | -4.1 Million SEK | -46.43% |
| 2020 Q4 | -2.69 Million SEK | 34.34% |
| 2020 FY | -13.69 Million SEK | -21.46% |
| 2019 Q4 | -273 Thousand SEK | 96.26% |
| 2019 FY | -11.27 Million SEK | -240.6% |
| 2019 Q3 | -7.3 Million SEK | -305.56% |
| 2019 Q2 | -1.8 Million SEK | 10.0% |
| 2019 Q1 | -2 Million SEK | 8.34% |
| 2018 FY | 8.01 Million SEK | 175.93% |
| 2018 Q4 | -2.18 Million SEK | -45.47% |
| 2018 Q3 | -1.5 Million SEK | -110.07% |
| 2018 Q1 | -3.1 Million SEK | -192.45% |
| 2018 Q2 | 14.9 Million SEK | 580.65% |
| 2017 FY | -10.56 Million SEK | 1.7% |
| 2017 Q3 | -2.3 Million SEK | 39.47% |
| 2017 Q2 | -3.8 Million SEK | -11.76% |
| 2017 Q1 | -3.4 Million SEK | -357.6% |
| 2017 Q4 | -1.06 Million SEK | 53.91% |
| 2016 Q3 | -2.9 Million SEK | 14.71% |
| 2016 Q2 | -3.4 Million SEK | 5.56% |
| 2016 Q4 | -743 Thousand SEK | 74.38% |
| 2016 FY | -10.74 Million SEK | 32.57% |
| 2016 Q1 | -3.6 Million SEK | 14.93% |
| 2015 FY | -15.93 Million SEK | 13.83% |
| 2015 Q4 | -4.23 Million SEK | -5.8% |
| 2015 Q3 | -4 Million SEK | -8.11% |
| 2015 Q2 | -3.7 Million SEK | 5.13% |
| 2015 Q1 | -3.9 Million SEK | -39.89% |
| 2014 Q3 | -3.3 Million SEK | 44.07% |
| 2014 Q1 | -6.5 Million SEK | -30.94% |
| 2014 Q2 | -5.9 Million SEK | 9.23% |
| 2014 Q4 | -2.78 Million SEK | 15.52% |
| 2014 FY | -18.48 Million SEK | 5.14% |
| 2013 Q4 | -4.96 Million SEK | -21.07% |
| 2013 Q1 | -5.3 Million SEK | -0.99% |
| 2013 FY | -19.49 Million SEK | 47.86% |
| 2013 Q3 | -4.1 Million SEK | 21.15% |
| 2013 Q2 | -5.2 Million SEK | 1.89% |
| 2012 Q4 | -5.24 Million SEK | 0.0% |
| 2012 FY | -37.37 Million SEK | 40.56% |
| 2011 FY | -62.88 Million SEK | -282.17% |
| 2010 FY | -16.45 Million SEK | 51.02% |
| 2009 FY | -33.59 Million SEK | 33.19% |
| 2008 FY | -50.28 Million SEK | -29.13% |
| 2007 FY | -38.94 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AddLife AB (publ) | 190 Million SEK | -53.632% |
| Biotage AB (publ) | 246 Million SEK | -18.659% |
| Bonesupport Holding AB (publ) | 245.02 Million SEK | -19.133% |
| Elekta AB (publ) | 1.3 Billion SEK | 77.581% |
| iZafe Group AB (publ) | -32.17 Million SEK | 1007.226% |
| Ortivus AB (publ) | -18.24 Million SEK | 1699.89% |
| Ortivus AB (publ) | -18.24 Million SEK | 1699.89% |
| Q-linea AB (publ) | -229.36 Million SEK | 227.264% |
| S2Medical AB (publ) | -22.7 Million SEK | 1385.481% |
| Synsam AB (publ) | 311 Million SEK | 6.141% |